During the past decade, Hospital Nacional Guillermo Almenara Irigoyen conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 10 clinical trials were completed, i.e. on average, 166.7% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 3 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Nacional Guillermo Almenara Irigoyen" #1 sponsor was "University of Minnesota" with 3 trials, followed by "Bristol-Myers Squibb" with 2 trials sponsored, "Pfizer's Upjohn has merged with Mylan to form Viatris Inc." with 2 trials sponsored, "Universidad Peruana Cayetano Heredia" with 2 trials sponsored and "CardioKine Inc." with 2 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Nacional Guillermo Almenara Irigoyen" #1 collaborator was "National Institute of Allergy and Infectious Diseases (NIAID)" with 3 trials as a collaborator, "GlaxoSmithKline" with 2 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 2 trials as a collaborator, "National Institutes of Health (NIH)" with 2 trials as a collaborator and "ANRS, Emerging Infectious Diseases" with 1 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 26 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Nacional Guillermo Almenara Irigoyen" are "Epilepsy" (2 trials), "Acute Peripheral Arterial Occlusion" (1 trials), "Acute Respiratory Failure" (1 trials), "Breast Cancer Stage IIIA" (1 trials) and "Breast Cancer Stage IV" (1 trials). Many other conditions were trialed in "Hospital Nacional Guillermo Almenara Irigoyen" in a lesser frequency.

Most popular intervention types in "Hospital Nacional Guillermo Almenara Irigoyen" are "Drug" (17 trials), "Biological" (2 trials), "Device" (1 trials), "Dietary Supplement" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "1% Glycated Chitosan" (1 trials), "ABZ Placebo" (1 trials), "Abatacept" (1 trials) and "Albendazole" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Nacional Guillermo Almenara Irigoyen" are 23 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Hospital Nacional Guillermo Almenara Irigoyen". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Hospital Nacional Guillermo Almenara Irigoyen, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Nacional Guillermo Almenara Irigoyen, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".